We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
DiaTech Oncology Receives New York State Clinical Laboratory Permit
News

DiaTech Oncology Receives New York State Clinical Laboratory Permit

DiaTech Oncology Receives New York State Clinical Laboratory Permit
News

DiaTech Oncology Receives New York State Clinical Laboratory Permit

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "DiaTech Oncology Receives New York State Clinical Laboratory Permit"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

DiaTech Oncology announced that the company has received a Clinical Laboratory Permit from the New York State Department of Health (NYS DOH). DiaTech’s predictive assay test — which guides the treating oncologist to the most effective chemotherapy for inducing cell death in the malignant cells of a particular cancer patient — is now available to patients and physicians in all 50 states.

In clinical trials and published research, use of DiaTech Oncology’s test — the MiCK® assay or Correct Chemo® — has consistently shown an increase in complete or partial response rates, longer time to relapse and a trend to longer survival times for more than 50 types of cancers, including lung, breast, colorectal, stomach, prostate, liver, ovarian, esophageal, bladder, non-Hodgkin lymphoma, leukemia and other cancers.

“New York State has the most stringent requirements for laboratory test approval in the United States,” says Garry Latimer, DiaTech CEO. “Receiving this permit is great news for cancer patients. It affirms that our CAP-accredited, CLIA-certified laboratory meets the highest standards for accurate and reliable clinical laboratory services.”

“DiaTech’s predictive assay — the only test on the market that guides the treating oncologist to the most effective chemotherapy for inducing apoptotic cell death in the malignant cells of a particular cancer patient — is now available to more cancer patients and oncologists than ever before,” states Dr. Cary Presant, DiaTech Chief Medical Officer. “Our clinical studies consistently reveal that patients treated with MiCK assay-guided chemotherapy demonstrate longer survival times and lower costs, and our studies are continuing to produce unexpected new leads for innovative therapeutic strategies.”

DiaTech’s patented MiCK assay measures apoptosis, or cell death, in the cancer cells of chemotherapy patients. Tumor cells are exposed to multiple doses of several chemotherapeutic drugs, either as single drugs or combinations. An algorithm monitors and computes the amount of cell death and determines a drug sensitivity “score” of the patients’ tumor cells.

Advertisement